Pricing Log in Create free account

Insulet Corporation (PODD) vs 10x Genomics (TXG)

Insulet Corporation and 10x Genomics are both Medical Devices companies. Insulet Corporation is the larger, with a market value of $10.8B against $7.6B — 1.4× the size. 10x Genomics has negative trailing earnings, so its P/E is not meaningful; Insulet Corporation trades at 25.2×. Insulet Corporation grew revenue faster over the last twelve months: 26.5% against −4.28%. Insulet Corporation has the higher net margin (13.5% vs −12.2%) and the higher return on invested capital (18.8% vs −20.2%). Across the 20 metrics below, Insulet Corporation leads on 16 and 10x Genomics on 4.

Valuation

Metric PODD TXG Medical Devices median
P/E 25.23 n/m 25.58
P/S 3.37 12.35 2.54
P/B 7.56 9.23 2.48
Price to free cash flow 46.37 63.28 28.81
EV/EBITDA 16.05 n/m 11.51
EV/Sales 3.49 11.51 2.72
Earnings yield 3.96% (1.01%) (12.82%)
Free cash flow yield 2.16% 1.58% (8.18%)

Profitability

Metric PODD TXG Medical Devices median
Gross margin 71.88% 70.03% 57.76%
Operating margin 18.43% (14.33%) (15.07%)
Net margin 13.45% (12.18%) (14.45%)
Free cash flow margin 8.15% 19.68% (3.88%)
Return on equity 28.94% (9.40%) (10.35%)
Return on assets 13.31% (7.47%) (17.26%)
Return on invested capital 18.77% (20.20%) (5.27%)

Growth

Metric PODD TXG Medical Devices median
Revenue growth (TTM) 26.46% (4.28%) 10.41%
EPS growth (last fiscal year) (39.79%) 76.97% 28.17%
Revenue growth, 5-year CAGR 24.53% 16.55% 15.74%
Net income growth, 5-year CAGR 105.15% 0.00% 0.00%

Health

Metric PODD TXG Medical Devices median
Debt to equity 0.61 0.00 0.04
Current ratio 2.51 5.69 2.74
Net debt to EBITDA 0.41 30.49 0.54

Dividend

Metric PODD TXG Medical Devices median
Dividend yield — — 1.02%
Payout ratio — — 0.37

Size

Metric PODD TXG Medical Devices median
Market cap 10.83b 7.56b 239.53m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack